BR112013007329A2 - método para diagnostificar o estado de doença de lyme em um mamífero, e, composição - Google Patents

método para diagnostificar o estado de doença de lyme em um mamífero, e, composição

Info

Publication number
BR112013007329A2
BR112013007329A2 BR112013007329A BR112013007329A BR112013007329A2 BR 112013007329 A2 BR112013007329 A2 BR 112013007329A2 BR 112013007329 A BR112013007329 A BR 112013007329A BR 112013007329 A BR112013007329 A BR 112013007329A BR 112013007329 A2 BR112013007329 A2 BR 112013007329A2
Authority
BR
Brazil
Prior art keywords
mammal
burgdorferi
lyme disease
composition
disease state
Prior art date
Application number
BR112013007329A
Other languages
English (en)
Inventor
Bettina Wagner
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of BR112013007329A2 publication Critical patent/BR112013007329A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

método para diagnostificar o estado de doença de lyme em um mamífero, e, composição. é fornecido um método para diagnosticar o estado de doença de lyme em um mamífero. o método envolve determinar, em uma amostra biológica obtida ou derivada de um mamíffero, anticorpos para proteínas de superfície externa (outer surface proteins, osp) ospa, ospc, e ospf de borrelia burgdorferi (b.burgdorferi). baseado na determinação dos anticorpos para ospa, ospc e ospf, o mamífero pode ser diagnosticado como vacinado, não-vacinado, infectado ou não infectado com b. burgdorferi. também podem ser identificados mamíferos que têm infecção por b. burgdorferi incial, intermeduiária ou crônica. o método é especialmente adequado para uso com cavalos e cães. antígenos de b. burgdorferi recombinantes ou isolados e composições que os contêm também são fornecidos.
BR112013007329A 2010-09-27 2011-09-27 método para diagnostificar o estado de doença de lyme em um mamífero, e, composição BR112013007329A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38669410P 2010-09-27 2010-09-27
PCT/US2011/053359 WO2012047607A2 (en) 2010-09-27 2011-09-27 Methods for diagnosing lyme disease

Publications (1)

Publication Number Publication Date
BR112013007329A2 true BR112013007329A2 (pt) 2016-07-19

Family

ID=45928310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007329A BR112013007329A2 (pt) 2010-09-27 2011-09-27 método para diagnostificar o estado de doença de lyme em um mamífero, e, composição

Country Status (11)

Country Link
US (1) US8946393B2 (pt)
EP (1) EP2622346A4 (pt)
JP (1) JP2013539032A (pt)
KR (1) KR20130101067A (pt)
CN (1) CN103229055A (pt)
BR (1) BR112013007329A2 (pt)
CA (1) CA2812759A1 (pt)
MX (1) MX2013003609A (pt)
RU (1) RU2013118647A (pt)
WO (1) WO2012047607A2 (pt)
ZA (1) ZA201302402B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT106942B (pt) 2013-05-15 2020-09-10 STAB VIDA, Investigação e Serviços em Ciências Biológicas, Lda Biochip (1) e bouquet de 16 antigénios (2) para a deteção da doença de lyme aguda e crónica
US10457721B2 (en) 2014-08-11 2019-10-29 University Of Massachusetts Anti-OSPA antibodies and methods of use
CN104374921B (zh) * 2014-11-21 2016-09-07 安徽医科大学 一种用于莱姆病鞭毛抗原免疫血清学诊断的蛋白质芯片及其制备方法和应用
CN108139401B (zh) 2015-09-25 2022-02-18 凯杰科技有限公司 诊断莱姆病并用于预测治疗后莱姆病螺旋体消除的组合物和方法
CN105524989A (zh) * 2015-12-31 2016-04-27 中国疾病预防控制中心传染病预防控制所 用于检测莱姆病螺旋体的rpa引物和探针及检测方法
CN105628918A (zh) * 2016-02-04 2016-06-01 浙江大学 一种蜱传莱姆病伯氏疏螺旋体检测试剂及应用
KR20210084485A (ko) * 2018-10-01 2021-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 다중 항체 이소타입의 동시 분리능을 갖는 고 특이성 및 민감도 면역 흡착제 진단 분석
US20230324382A1 (en) * 2022-02-01 2023-10-12 Trustees Of Tufts College Antiphospholipid antibodies for the diagnosis of lyme disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US5620862A (en) 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease
EP0757556B1 (en) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Borrelia burgdorferi bacterin
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
CA2197712A1 (en) 1994-08-17 1996-02-22 Reinhard Wallich Vaccines containing borrelia burgdorferi ospg
US5853987A (en) * 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
WO1997015600A1 (en) 1995-10-26 1997-05-01 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Tick (ixodes scapularis) vector saliva-induced lyme disease spirochete (borrelia burgdorferi) antigens as vaccine candidates
US6716574B2 (en) * 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
WO1997042221A1 (en) * 1996-05-02 1997-11-13 Statens Seruminstitut Novel osp-c derived peptide fragments
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
AU8177298A (en) 1997-06-30 1999-01-19 The Administrators Of The Tulane Eductional Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6610838B1 (en) * 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
JP3631960B2 (ja) 1998-07-31 2005-03-23 ガンダーセン ルテラン メディカル ファウンデイション インコーポレイテッド ワクチンとしてのボレリアブルグドルフェリ外部表面タンパク質ｃ（ｏｓｐｃ）のボレリアシダルエピトープの使用
WO2000018791A1 (en) * 1998-09-29 2000-04-06 Statens Serum Institut Ligand presenting assembly (lpa), method of preparation and uses thereof
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2000078800A2 (en) * 1999-06-18 2000-12-28 Medimmune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
US20030134345A1 (en) * 2001-07-17 2003-07-17 Michael Brunner Serological assay for detection of antigens sequested within immune complexes
FI112544B (fi) * 2001-11-26 2003-12-15 Bortech Oy Menetelmä varhais- ja myöhäisvaiheen Lymen borrelioosin diagnosoimiseksi
WO2004103269A2 (en) 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
US7390626B2 (en) 2005-02-25 2008-06-24 Immunosciences Lab., Inc. Methods and kit for diagnosing tick borne illnesses
CN101374858A (zh) * 2005-11-29 2009-02-25 弗吉尼亚州立大学 多价嵌合ospc疫苗原及诊断抗原
CA2631733C (en) * 2005-11-29 2017-08-01 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen
WO2007133623A2 (en) 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
US8129165B2 (en) 2006-09-15 2012-03-06 Intercell Ag Borrelia antigens
WO2009033163A2 (en) 2007-09-07 2009-03-12 The Regents Of The University Of California Borrelia diagnostics and screening methods
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
WO2011068844A1 (en) 2009-12-01 2011-06-09 Temple Douglas Borrelia burgdorferi bacterial antigen diagnostic test using polymeric bait containing capture particles
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー

Also Published As

Publication number Publication date
MX2013003609A (es) 2013-10-17
US20130273572A1 (en) 2013-10-17
EP2622346A2 (en) 2013-08-07
US8946393B2 (en) 2015-02-03
KR20130101067A (ko) 2013-09-12
ZA201302402B (en) 2014-06-25
EP2622346A4 (en) 2014-04-16
JP2013539032A (ja) 2013-10-17
CN103229055A (zh) 2013-07-31
RU2013118647A (ru) 2014-11-10
WO2012047607A3 (en) 2012-08-16
CA2812759A1 (en) 2012-04-12
WO2012047607A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
BR112013007329A2 (pt) método para diagnostificar o estado de doença de lyme em um mamífero, e, composição
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
Sousa et al. Molecular and serological detection of tick-borne pathogens in dogs from an area endemic for Leishmania infantum in Mato Grosso do Sul, Brazil
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
EP3587439A3 (en) Improved quantification of vaccine compositions
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201590184A1 (ru) Вакцина на основе микобактериальных антигенов
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
Cotté et al. Differential expression of Ixodes ricinus salivary gland proteins in the presence of the Borrelia burgdorferi sensu lato complex
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
JP2013539032A5 (pt)
Lopez et al. Sequence analysis and serological responses against Borrelia turicatae BipA, a putative species-specific antigen
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
Moming et al. Mapping of B-cell epitopes on the N-terminal and C-terminal segment of nucleocapsid protein from Crimean-Congo hemorrhagic fever virus
BR112014020513A2 (pt) Métodos e sistemas para amplificação de sinal de bioensaios
WO2013116668A8 (en) Diagnostic peptides for lyme disease
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.